HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
Open Access
- 13 February 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (2) , e70088
Abstract
Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p < 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p < 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.Keywords
This publication has 30 references indexed in Scilit:
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantationBone Marrow Transplantation, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research StudyTransplantation and Cellular Therapy, 2015
- Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemiaBlood, 2007
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeJournal of Clinical Oncology, 2005
- Amino Acid Difference Formula to Help Explain Protein EvolutionScience, 1974